| Identification | Back Directory | [Name]
3-Pyridinecarboxamide, N-[(2R,3S,4S,4aS,8aS)-4-(3,5-dihydroxybenzoyl)decahydro-3,4a,8,8-tetramethyl-2-naphthalenyl]- | [CAS]
1619983-52-6 | [Synonyms]
AQX-435
3-Pyridinecarboxamide, N-[(2R,3S,4S,4aS,8aS)-4-(3,5-dihydroxybenzoyl)decahydro-3,4a,8,8-tetramethyl-2-naphthalenyl]- | [Molecular Formula]
C27H34N2O4 | [MOL File]
1619983-52-6.mol | [Molecular Weight]
450.57 |
| Chemical Properties | Back Directory | [Boiling point ]
661.8±43.0 °C(Predicted) | [density ]
1.23±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
8.60±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
AQX-435 is a potent SHIP1 phosphatase activator. AQX-435 reduces PI3K activation downstream of the B-cell receptor (BCR) and induces apoptosis of malignant B cells, and reduces lymphoma growth[1][2]. | [in vivo]
AQX-435 (10 mg/kg; i.p.; 5 days) significantly reduced the volume of TMD8 tumors[1].
AQX-435 (50 mg/kg; ip) inhibits DLBCL PDX tumors growth[1].
AQX-435 reduced AKT phosphorylation and growth of DLBCL in vivo and cooperated with ibrutinib for tumor growth inhibition[1]. | Animal Model: | NOD.Cg-Prkdc scidIl2rgtm1Wjl/SzJ mice (NSG mice) (TMD8 tumors)[1] | | Dosage: | 10 mg/kg | | Administration: | I.p.; in 7-day cycles each comprising 5 days of AQX-435 followed by 2 days with no drug | | Result: | Reduced the volume of TMD8 tumors.
|
| [References]
[1] Lyoyd F. MACKENZIE, et al. Ship1 modulators and methods related thereto.WO2014110036A1.
[2] Lemm EA, et al. Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells. Clin Cancer Res. 2020;26(7):1700-1711. DOI:10.1158/1078-0432.CCR-19-2202 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|